K Number
K230780
Device Name
MFG-05
Date Cleared
2023-10-05

(197 days)

Product Code
Regulation Number
876.5320
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
MFG-05 is intended to provide entirely non-invasive electromagnetic stimulation of the pelvic floor musculature for the purpose of rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence.
Device Description
The MFG-05 is a non-invasive therapeutic device produces a magnetic field that interacts with the tissues of the human body. By stimulation of the pelvic floor musculature, the MFG-05 helps to treat of male and female urinary incontinence. The device housing protects the patient from electrical shock and mechanical injuries. The device is a mobile standalone equipment with four wheels. One applicator is available for therapy and is positioned centrally under the pelvic floor of the patient while the patient is wearing sport pants or any other pants without metallic parts. The device is for prescription use and used by a trained medical professional in a professional healthcare facility. The main body of MFG-05 is used to control the function of magnetic stimulation. It is operated with parameters such as frequency, time and intensity. These parameters can be controlled by the user on screen display and with the help of a rotary knob at the user control panel.
More Information

emField - K203488

No
The description focuses on the physical mechanism of electromagnetic stimulation and user-controlled parameters (frequency, time, intensity). There is no mention of AI, ML, data analysis, or adaptive algorithms.

Yes
The "Device Description" explicitly states, "The MFG-05 is a non-invasive therapeutic device". Additionally, its intended use is for "rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence", which is a therapeutic purpose.

No

The device description clearly states it is a "non-invasive therapeutic device" for the treatment of urinary incontinence by stimulating pelvic floor musculature, and it focuses on controlling parameters for therapy rather than gathering information or diagnosing a condition.

No

The device description clearly outlines a physical device with a housing, wheels, an applicator, a screen display, and a rotary knob, indicating it is a hardware device that utilizes magnetic stimulation.

Based on the provided information, the MFG-05 device is not an In Vitro Diagnostic (IVD).

Here's why:

  • Intended Use: The intended use clearly states that the device is for "entirely non-invasive electromagnetic stimulation of the pelvic floor musculature for the purpose of rehabilitation... and restoration of neuromuscular control for the treatment of male and female urinary incontinence." This describes a therapeutic treatment applied directly to the patient's body.
  • Device Description: The description details a device that produces a magnetic field to interact with tissues and stimulate muscles. This is a physical intervention, not a test performed on samples taken from the body.
  • Lack of IVD Characteristics: There is no mention of analyzing samples (blood, urine, tissue, etc.), detecting substances, or providing diagnostic information based on laboratory tests.

In Vitro Diagnostics (IVDs) are medical devices used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. The MFG-05 does not fit this definition. It is a therapeutic device.

N/A

Intended Use / Indications for Use

MFG-05 is intended to provide entirely non-invasive electromagnetic stimulation of the pelvic floor musculature for the purpose of rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence.

Product codes

KPI

Device Description

The MFG-05 is a non-invasive therapeutic device produces a magnetic field that interacts with the tissues of the human body. By stimulation of the pelvic floor musculature, the MFG-05 helps to treat of male and female urinary incontinence.

The device housing protects the patient from electrical shock and mechanical injuries. The device is a mobile standalone equipment with four wheels. One applicator is available for therapy and is positioned centrally under the pelvic floor of the patient while the patient is wearing sport pants or any other pants without metallic parts. The device is for prescription use and used by a trained medical professional in a professional healthcare facility. The main body of MFG-05 is used to control the function of magnetic stimulation. It is operated with parameters such as frequency, time and intensity. These parameters can be controlled by the user on screen display and with the help of a rotary knob at the user control panel.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

pelvic floor musculature

Indicated Patient Age Range

Adults only

Intended User / Care Setting

a trained medical professional in a professional healthcare facility.

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

The MFG-05 has been investigated and tested against and complies with the following voluntary standards: ES60601-1:2005/(R)2012 & A1:2012, C1:2009/(R)2012 & A2:2010/(R)2012 (Cons. Text), IEC 60601-1-2 Edition 4.1 2020-09, IEC 60601-1-6 Edition 3.1 2013-10, IEC 60601-2-10 Edition 2.1 2016-04, IEC 62366-1 Edition 1.0 2015-02, IEC 62304 Edition 1.1 2015-06, ISO 14971 Third Edition 2019-12.

Preclinical Testing Results:

  • Performance testing per IEC 60601-2-10
  • Magnetic Field testing
  • SAR analysis and Tissue Heating study

Key results: The testing above confirmed that the applicator operates within the magnetic field intensity specifications and that the tissue being treated by the device does not present an appreciable rise in temperature at maximum intensity to cause a risk to the patient. Testing has been performed and all components, subassemblies and/or full devices and systems have met the required specifications for the completed tests.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

HPM-6000UF-K181497

Reference Device(s)

emField - K203488

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 876.5320 Nonimplanted electrical continence device.

(a)
Identification. A nonimplanted electrical continence device is a device that consists of a pair of electrodes on a plug or a pessary that are connected by an electrical cable to a battery-powered pulse source. The plug or pessary is inserted into the rectum or into the vagina and used to stimulate the muscles of the pelvic floor to maintain urinary or fecal continence. When necessary, the plug or pessary may be removed by the user. This device excludes an AC-powered nonimplanted electrical continence device and the powered vaginal muscle stimulator for therapeutic use (§ 884.5940).(b)
Classification. Class II (performance standards).

0

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the symbol of the Department of Health & Human Services on the left and the FDA acronym along with the full name of the agency on the right. The FDA part of the logo is in blue, with the acronym in a square and the full name written out next to it.

October 5, 2023

Zimmer MedizinSysteme GmbH % Scott Blood Principal Regulatory Consultant Ouality and Regulatory Services 151 Gleasondale Road Stow, MA 01775

K230780 Re: Trade/Device Name: MFG-05 Regulation Number: 21 CFR§ 876.5320 Regulation Name: Nonimplanted Electrical Continence Device Regulatory Class: II Product Code: KPI Dated: August 31, 2023 Received: September 5, 2023

Dear Scott Blood:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

1

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Jessica K. Nguyen -S

Jessica K. Nguyen, Ph.D. Assistant Director DHT3B: Division of Reproductive, Gynecology and Urology Devices OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

2

Indications for Use

510(k) Number (if known) K230780

Device Name MFG-05

Indications for Use (Describe)

MFG-05 is intended to provide entirely non-invasive electromagnetic stimulation of the pelvic floor musculature for the purpose of rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence.

Type of Use (Select one or both, as applicable)
☑ Prescription Use (Part 21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

3

K230780 Page 1 of 6

Image /page/3/Picture/1 description: The image shows the logo for Zimmer MedizinSysteme. The logo consists of the word "zimmer" in a sans-serif font, with a horizontal line above the "z". Below the word "zimmer" is the text "MedizinSysteme" in a smaller font. The logo is in gray color.

510(k) Summary MFG-05

    1. Basic Information-Submitter:

| 510(k) Owner: | Zimmer MedizinSysteme GmbH
Junkersstrasse 9
89231 Neu-Ulm
Germany
Establishment Registration: 8010720 |
|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Ms. Ute Killet
Manager Regulatory Affairs
Phone: +49-7319761-625
Fax: +49-731-9761-118
E-Mail: u.killet@zimmer.de |
| Official Contact: | Mr. Scott Blood
Principle Consultant
Phone: 978.729.5978
Fax: +49-731-9761-118
E-mail: scottqara@gmail.com |
| Date Summary Prepared: | October 5, 2023 |
| 2. Device Name: | |
| | Trade Name: MFG-05
Common Name: Stimulator, Electrical, Non-implantable, For Incontinence
Regulation Name: Nonimplanted electrical continence device
Regulation Number: 21 CFR 876.5320
Product Code: KPI
Classification: Class II |
| 3. Predicate Devices: | |
| | Company Name: HPM-6000UF-K181497
BTL Industries, Inc.
The predicate has not been subject to a design-related recall |
| | Reference Device: emField - K203488
Company Name: Zimmer MedizinSysteme GmbH |

4

  • Device Description: 4.
    The MFG-05 is a non-invasive therapeutic device produces a magnetic field that interacts with the tissues of the human body. By stimulation of the pelvic floor musculature, the MFG-05 helps to treat of male and female urinary incontinence.

The device housing protects the patient from electrical shock and mechanical injuries. The device is a mobile standalone equipment with four wheels. One applicator is available for therapy and is positioned centrally under the pelvic floor of the patient while the patient is wearing sport pants or any other pants without metallic parts. The device is for prescription use and used by a trained medical professional in a professional healthcare facility. The main body of MFG-05 is used to control the function of magnetic stimulation. It is operated with parameters such as frequency, time and intensity. These parameters can be controlled by the user on screen display and with the help of a rotary knob at the user control panel.

Indications for Use Statement:

MFG-05 is intended to provide entirely non-invasive electromagnetic stimulation of the pelvic floor musculature for the purpose of rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male urinary incontinence.

ATTRIBUTESUBJECT DEVICEPREDICATE DEVICEREFERENCE DEVICE
Zimmer MedizinSysteme
GmbH
MFG-05
This SubmissionBTL Industries, Inc.
HPM-6000UF
K181497Zimmer MedizinSysteme
GmbH
emField
K203488
Intended UseMFG-05 is intended to
provide entirely non-
invasive electromagnetic
stimulation of the pelvic
floor musculature for the
purpose of rehabilitation of
weak pelvic muscles and
restoration of
neuromuscular control for
the treatment of male and
female urinary
incontinence.HPM-6000UF is intended
to provide entirely non-
invasive electromagnetic
stimulation of the pelvic
floor musculature for the
purpose of rehabilitation of
weak pelvic muscles and
restoration of
neuromuscular control for
the treatment of male and
female urinary
incontinence.The emField is indicated to
be used for:
Relaxation of muscle spasms;Prevention or retardation of disuse atrophy;Increasing local blood circulation;Muscle re-education;Immediate post-surgical stimulation of calf muscles to prevent venous thrombosis; andMaintaining or increasing range of motion.

The Indications for Use statement of MFG-05 is identical to that of the predicate device.

5

    1. Technological Characteristics:
      The MFG-05 device has similar technological characteristics and principles of operation as its predicate device. The MFG-05 device and its predicate device are comprised of a system console and one applicator. The system console consists of electromagnetic field generators, a computer and the touch-screen control panel. The technological similarities and differences between the subject device and the predicate device are described below in the comparison table

The MFG-05 device was developed based on the reference device (emField) and has equivalent technology and principles of operation as the reference device. The emField device allows the use of one large applicator or one small applicator to be used only one at a time. The MFG-05 has the small applicator removed. The MFG-05 and its reference device generate both a magnetic field by applying a strong current to an applicator. The subject device has all features of the reference device.

The technological characteristics of the MFG-05 does not raise any different questions of safety or effectiveness.

SUBJECT DEVICEPREDICATE DEVICEREFERENCE DEVICE
Technological
CharacteristicsZimmer MedizinSysteme
GmbH
MFG-05
This SubmissionBTL Industries, Inc.
HPM-6000UF
K181497Zimmer MedizinSysteme
GmbH
emField
K203488
Clinical UsePrescription UsePrescription UsePrescription Use
Applicable
PatientsMale and Female, Adults
onlyMale and Female, Adults onlyAdults only
Primary
FunctionMuscle stimulationMuscle stimulationMuscle stimulation
Principle of
ActionInitiating action potential of
nerves results in muscle
contractionInitiating action potential of
nerves results in muscle
contractionInitiating action potential of
nerves results in muscle
contraction
Type of EnergyMagnetic fieldMagnetic fieldMagnetic field
Energy Source100 - 120 V AC, 50/60 Hz,
max. 2.7 kVA; 220 - 240 V
AC, 50/60Hz, max. 2.7 kVA100 - 240 V AC, 50 - 60 Hz,
max 14 A100-240 V AC, 50-60 Hz,
max 12.5 A
Number of
output channels112
Magnetic Field
IntensityApplicator:
0.5 - 1.5 T +/-20%0.7 - 2.5 TLarge applicator:
0.5 – 1.5 T +/-20%
Small applicator:
0.5 - 2.0 T +/-20%
Pulse Repetition
Rate1 – 150 Hz1 – 150 Hz1 – 150 Hz

6

SUBJECT DEVICEPREDICATE DEVICEREFERENCE DEVICE
Technological
CharacteristicsZimmer MedizinSysteme
GmbH
MFG-05
This SubmissionBTL Industries, Inc.
HPM-6000UF
K181497Zimmer MedizinSysteme
GmbH
emField
K203488
Pulse Width400 us (+/- 20%)280 us (+/- 20%)Large applicator:
400 us +/- 20%
Small applicator:
250 us +/- 20%
Shape of
Stimulation
PulseSymmetrical Biphasic Sine
WaveDual phase, rectangular
pulsesSymmetrical Biphasic Sine
Wave
Therapy TimeUp to 60 minUp to 60 minUp to 60 min
InterfaceTouchscreenTouchscreenTouchscreen
Firmware
controlledYesYesYes
Software Level
of ConcernModerateModerateModerate
Environmental
SpecificationsFor indoor use onlyFor indoor use onlyFor indoor use only
FeedbackBy patientBy patientBy patient
Operating
Temperature10° C to 30° C
(50° F to 86° F)+10° C to +30° C
(50° F to 86°F)10° C to 30° C
Main Unit
Dimensions
(WxHxD)455x1000x417 mm500×970×580 mm
(20×38×23 in)542x501x993 mm
Applicator
Dimensions
(WxHxD)170x48x402 mm730x730x730 mm
(29x29x29 in)161x41.5x300.5 mm
System WeightApprox. 60 kg (No Safe
Working Load)46 kg (101 lb)Approx. 60 kg

There are a few technological differences between the subject device and the predicate device, including differences in stimulation waveform parameters (i.e., magnetic field intensity, pulse width) and main unit dimensions. Performance testing were provided to demonstrate that these different do not affect the safety or performance of the device as compared to the predicate device.

7

6. Performance data

The MFG-05 has been investigated and tested against and complies with the following voluntary standards:

| Standards | Standards
Organization | Standards Title |
|----------------------------------------------------------------------------------------------|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ES60601-1:2005/(R)2012
& A1:2012,
C1:2009/(R)2012 &
A2:2010/(R)2012 (Cons.
Text) | ANSI/AAMI | Medical electrical equipment – Part 1: General requirements for
basic safety and essential performance |
| 60601-1-2 Edition 4.1
2020-09 | IEC | Medical electrical equipment – Part 1-2: General requirements for
basic safety and essential performance – Collateral standard:
Electromagnetic disturbances – Requirements and tests |
| 60601-1-6 Edition 3.1
2013-10 | IEC | Medical electrical equipment – Part 1-6: General requirements for
basic safety and essential performance - Collateral standard:
Usability |
| 60601-2-10 Edition 2.1
2016-04 | IEC | Medical electrical equipment - Part 2-10: Particular requirements for
the basic safety and essential performance of nerve and muscle
stimulators |
| 62366-1 Edition 1.0
2015-02 | IEC | Medical devices - Part 1: Application of usability engineering to
medical devices |
| 62304 Edition 1.1 2015-
06 | IEC | Medical devices software -software life cycle processes |
| 14971 Third Edition
2019-12 | ISO | Medical devices – Application of risk management to medical devices |

The following table shows a comparison of the performance testing in comparison to the predicate device:

SUBJECT DEVICEPREDICATE DEVICE
StandardsZimmer MedizinSyteme
GmbHBTL Industries, Inc.
MFG-05
This SubmissionHPM-6000UF
K181497
ANSI/AAMI
ES60601-1XX
IEC 60601-1-2XX
IEC 60601-2-10XX
ISO 10993-1
ISO 10993-5
ISO 10933-10Not applicable (no patient-
contacting
materials)X

According to this comparison table all required performance tests were conducted and show substantial equivalence with the predicate device.

8

Preclinical Testing Results

The following tests were performed on the subject device in addition to the testing listed above:

  • Performance testing per IEC 60601-2-10 ●
  • Magnetic Field testing
  • SAR analysis and Tissue Heating study

The testing above confirmed that the applicator operates within the magnetic field intensity specifications and that the tissue being treated by the device does not present an appreciable rise in temperature at maximum intensity to cause a risk to the patient.

Testing has been performed and all components, subassemblies and/or full devices and systems have met the required specifications for the completed tests.

    1. Conclusion:
      There are no differences with respect to the indications for use and many of the technological characteristics between the MFG-05 and the predicate device. The minor differences mentioned above do not raise new questions of safety or effectiveness. The performance testing provided supports that the MFG-05 is as safe and effective as the predicate device, and therefore is substantially equivalent.